-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Remember a news from the end of last year? On the evening of December 12, 2020, AstraZeneca announced that it had acquired rare disease giant Yalixiong Pharmaceutical with a huge sum of 39 billion U.
S.
dollars.
This move brought AstraZeneca a rare disease product line and related talents (details >>), On July 21 this year, the acquisition was officially completed, and AstraZeneca began to enter the field of rare diseases
.
S.
dollars.
This move brought AstraZeneca a rare disease product line and related talents (details >>), On July 21 this year, the acquisition was officially completed, and AstraZeneca began to enter the field of rare diseases
.
According to Dami’s understanding, today, AstraZeneca China announced to its employees-AstraZeneca China Rare Diseases Business Unit was formally established, and the former head of the Strategic Project Management Office of AstraZeneca China’s Oncology Business Unit and the marketing and sales of smetinib were appointed Executive Director Wu Yun serves as the head of the rare disease business department and reports directly to Wang Lei, AstraZeneca's global executive vice president, international business and president of China
.
.
AstraZeneca's rare disease drug Smeltinib is a highly selective MEK inhibitor originally developed by Array Biopharmaceuticals.
On April 10 last year, Smeltinib was approved by the US FDA for use in children 2 years and older.
Type 1 neurofibromatosis (NF1) and symptomatic, inoperable plexiform neurofibroma (PN).
The drug is not currently on the market in China.
In March this year, it was introduced in the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
It is used to treat neurofibromatosis type 1 (NF1)
.
On April 10 last year, Smeltinib was approved by the US FDA for use in children 2 years and older.
Type 1 neurofibromatosis (NF1) and symptomatic, inoperable plexiform neurofibroma (PN).
The drug is not currently on the market in China.
In March this year, it was introduced in the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
It is used to treat neurofibromatosis type 1 (NF1)
.
Wu Yun used to be the marketing director of GlaxoSmithKline's China vaccine business.
In July last year, Wu Yun joined AstraZeneca China as the executive director of smetinib marketing, responsible for listing matters, and also responsible for leading the strategic projects of AstraZeneca's China cancer business Office team
.
In July last year, Wu Yun joined AstraZeneca China as the executive director of smetinib marketing, responsible for listing matters, and also responsible for leading the strategic projects of AstraZeneca's China cancer business Office team
.
It is reported that after the establishment of the new rare disease business unit, the original AstraZeneca Smetinib team and the Chinese team of Alex Brothers will be merged into this new business unit
.
.
Rare disease drugs have become the new darling of multinational pharmaceutical companies in recent years.
In 2018, Takeda Pharmaceuticals spent US$65 billion to acquire the rare disease giant Shire, which became the largest acquisition in the pharmaceutical field that year , and it has made Takeda Pharmaceuticals now a global pharmaceutical company.
Ranked 10th among enterprises (for details, see MRCLUB historical news: the third largest single in the new year! Takeda completed the acquisition of Shire today)
.
In 2018, Takeda Pharmaceuticals spent US$65 billion to acquire the rare disease giant Shire, which became the largest acquisition in the pharmaceutical field that year , and it has made Takeda Pharmaceuticals now a global pharmaceutical company.
Ranked 10th among enterprises (for details, see MRCLUB historical news: the third largest single in the new year! Takeda completed the acquisition of Shire today)
.
The fourth and fifth batches of national procurement are implemented, and many foreign enterprise promoters are affected
As of today, two batches of national procurement have been launched this year.
As you can see, in the past few months, many foreign company promoters have been affected by the company's adjustments
.
As you can see, in the past few months, many foreign company promoters have been affected by the company's adjustments
.
This week, two foreign companies made adjustments, mainly because the fourth batch of national sourcing and the fifth batch of national sourcing were not selected
.
.
One of the foreign companies, because they lost the fifth batch of national procurement, notified the team to adjust last week.
Today, many people have gone to Beijing, Hangzhou and other places to sign the resignation agreement.
The compensation is N+2.
After the results were announced, some people left and some were transferred.
After leaving another group this time, only a small number of dedicated line representatives were retained
.
Today, many people have gone to Beijing, Hangzhou and other places to sign the resignation agreement.
The compensation is N+2.
After the results were announced, some people left and some were transferred.
After leaving another group this time, only a small number of dedicated line representatives were retained
.
Another foreign company failed in the fourth batch of national sourcing products because of its variety, and the product will soon be handed over to other companies for promotion.
It is estimated that some of the promoters responsible for the product will also be affected
.
It is estimated that some of the promoters responsible for the product will also be affected
.
On February 8 this year, the fourth batch of national sources announced the results of the selection of 45 varieties, which began at the end of April and were implemented in all provinces across the country until the end of May.
On June 28, the results of the fifth batch of 62 varieties of national sources were announced.
, And it is expected to be implemented nationwide in October
.
On June 28, the results of the fifth batch of 62 varieties of national sources were announced.
, And it is expected to be implemented nationwide in October
.
In the past few months, many foreign and domestic companies have been affected by this to make organizational structure adjustments, so I will not list them all here
.
.
It is expected that by the end of this year, the sixth batch of national procurement may start
.
.
Remember a news from the end of last year? On the evening of December 12, 2020, AstraZeneca announced that it had acquired rare disease giant Yalixiong Pharmaceutical with a huge sum of 39 billion U.
S.
dollars.
This move brought AstraZeneca a rare disease product line and related talents (details >>), On July 21 this year, the acquisition was officially completed, and AstraZeneca began to enter the field of rare diseases
.
S.
dollars.
This move brought AstraZeneca a rare disease product line and related talents (details >>), On July 21 this year, the acquisition was officially completed, and AstraZeneca began to enter the field of rare diseases
.
According to Dami’s understanding, today, AstraZeneca China announced to its employees-AstraZeneca China Rare Diseases Business Unit was formally established, and the former head of the Strategic Project Management Office of AstraZeneca China’s Oncology Business Unit and the marketing and sales of smetinib were appointed Executive Director Wu Yun serves as the head of the rare disease business department and reports directly to Wang Lei, AstraZeneca's global executive vice president, international business and president of China
.
.
AstraZeneca's rare disease drug Smeltinib is a highly selective MEK inhibitor originally developed by Array Biopharmaceuticals.
On April 10 last year, Smeltinib was approved by the US FDA for use in children 2 years and older.
Type 1 neurofibromatosis (NF1) and symptomatic, inoperable plexiform neurofibroma (PN).
The drug is not currently on the market in China.
In March this year, it was introduced in the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
It is used to treat neurofibromatosis type 1 (NF1)
.
On April 10 last year, Smeltinib was approved by the US FDA for use in children 2 years and older.
Type 1 neurofibromatosis (NF1) and symptomatic, inoperable plexiform neurofibroma (PN).
The drug is not currently on the market in China.
In March this year, it was introduced in the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
It is used to treat neurofibromatosis type 1 (NF1)
.
Wu Yun used to be the marketing director of GlaxoSmithKline's China vaccine business.
In July last year, Wu Yun joined AstraZeneca China as the executive director of smetinib marketing, responsible for listing matters, and also responsible for leading the strategic projects of AstraZeneca's China cancer business Office team
.
In July last year, Wu Yun joined AstraZeneca China as the executive director of smetinib marketing, responsible for listing matters, and also responsible for leading the strategic projects of AstraZeneca's China cancer business Office team
.
It is reported that after the establishment of the new rare disease business unit, the original AstraZeneca Smetinib team and the Chinese team of Alex Brothers will be merged into this new business unit
.
.
Rare disease drugs have become the new darling of multinational pharmaceutical companies in recent years.
In 2018, Takeda Pharmaceuticals spent US$65 billion to acquire the rare disease giant Shire, which became the largest acquisition in the pharmaceutical field that year , and it has made Takeda Pharmaceuticals now a global pharmaceutical company.
Ranked 10th among enterprises (for details, see MRCLUB historical news: the third largest single in the new year! Takeda completed the acquisition of Shire today)
.
In 2018, Takeda Pharmaceuticals spent US$65 billion to acquire the rare disease giant Shire, which became the largest acquisition in the pharmaceutical field that year , and it has made Takeda Pharmaceuticals now a global pharmaceutical company.
Ranked 10th among enterprises (for details, see MRCLUB historical news: the third largest single in the new year! Takeda completed the acquisition of Shire today)
.
The fourth and fifth batches of national procurement are implemented, and many foreign enterprise promoters are affected
As of today, two batches of national procurement have been launched this year.
As you can see, in the past few months, many foreign company promoters have been affected by the company's adjustments
.
As you can see, in the past few months, many foreign company promoters have been affected by the company's adjustments
.
This week, two foreign companies made adjustments, mainly because the fourth batch of national sourcing and the fifth batch of national sourcing were not selected
.
.
One of the foreign companies, because they lost the fifth batch of national procurement, notified the team to adjust last week.
Today, many people have gone to Beijing, Hangzhou and other places to sign the resignation agreement.
The compensation is N+2.
After the results were announced, some people left and some were transferred.
After leaving another group this time, only a small number of dedicated line representatives were retained
.
Today, many people have gone to Beijing, Hangzhou and other places to sign the resignation agreement.
The compensation is N+2.
After the results were announced, some people left and some were transferred.
After leaving another group this time, only a small number of dedicated line representatives were retained
.
Another foreign company failed in the fourth batch of national sourcing products because of its variety, and the product will soon be handed over to other companies for promotion.
It is estimated that some of the promoters responsible for the product will also be affected
.
It is estimated that some of the promoters responsible for the product will also be affected
.
On February 8 this year, the fourth batch of national sources announced the results of the selection of 45 varieties, which began at the end of April and were implemented in all provinces across the country until the end of May.
On June 28, the results of the fifth batch of 62 varieties of national sources were announced.
, And it is expected to be implemented nationwide in October
.
On June 28, the results of the fifth batch of 62 varieties of national sources were announced.
, And it is expected to be implemented nationwide in October
.
In the past few months, many foreign and domestic companies have been affected by this to make organizational structure adjustments, so I will not list them all here
.
.
It is expected that by the end of this year, the sixth batch of national procurement may start
.
.
Remember a news from the end of last year? On the evening of December 12, 2020, AstraZeneca announced that it had acquired rare disease giant Yalixiong Pharmaceutical with a huge sum of 39 billion U.
S.
dollars.
This move brought AstraZeneca a rare disease product line and related talents (details >>), On July 21 this year, the acquisition was officially completed, and AstraZeneca began to enter the field of rare diseases
.
S.
dollars.
This move brought AstraZeneca a rare disease product line and related talents (details >>), On July 21 this year, the acquisition was officially completed, and AstraZeneca began to enter the field of rare diseases
.
According to Dami’s understanding, today, AstraZeneca China announced to its employees-AstraZeneca China Rare Diseases Business Unit was formally established, and the former head of the Strategic Project Management Office of AstraZeneca China’s Oncology Business Unit and the marketing and sales of smetinib were appointed Executive Director Wu Yun serves as the head of the rare disease business department and reports directly to Wang Lei, AstraZeneca's global executive vice president, international business and president of China
.
.
AstraZeneca's rare disease drug Smeltinib is a highly selective MEK inhibitor originally developed by Array Biopharmaceuticals.
On April 10 last year, Smeltinib was approved by the US FDA for use in children 2 years and older.
Type 1 neurofibromatosis (NF1) and symptomatic, inoperable plexiform neurofibroma (PN).
The drug is not currently on the market in China.
In March this year, it was introduced in the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
It is used to treat neurofibromatosis type 1 (NF1)
.
Child, child, kidOn April 10 last year, Smeltinib was approved by the US FDA for use in children 2 years and older.
Type 1 neurofibromatosis (NF1) and symptomatic, inoperable plexiform neurofibroma (PN).
The drug is not currently on the market in China.
In March this year, it was introduced in the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
It is used to treat neurofibromatosis type 1 (NF1)
.
Wu Yun used to be the marketing director of GlaxoSmithKline's China vaccine business.
In July last year, Wu Yun joined AstraZeneca China as the executive director of smetinib marketing, responsible for listing matters, and also responsible for leading the strategic projects of AstraZeneca's China cancer business Office team
.
Tumor tumor tumorIn July last year, Wu Yun joined AstraZeneca China as the executive director of smetinib marketing, responsible for listing matters, and also responsible for leading the strategic projects of AstraZeneca's China cancer business Office team
.
It is reported that after the establishment of the new rare disease business unit, the original AstraZeneca Smetinib team and the Chinese team of Alex Brothers will be merged into this new business unit
.
.
Rare disease drugs have become the new darling of multinational pharmaceutical companies in recent years.
In 2018, Takeda Pharmaceuticals spent US$65 billion to acquire the rare disease giant Shire, which became the largest acquisition in the pharmaceutical field that year , and it has made Takeda Pharmaceuticals now a global pharmaceutical company.
Ranked 10th among enterprises (for details, see MRCLUB historical news: the third largest single in the new year! Takeda completed the acquisition of Shire today)
.
Medicine Medicine MedicineIn 2018, Takeda Pharmaceuticals spent US$65 billion to acquire the rare disease giant Shire, which became the largest acquisition in the pharmaceutical field that year , and it has made Takeda Pharmaceuticals now a global pharmaceutical company.
Ranked 10th among enterprises (for details, see MRCLUB historical news: the third largest single in the new year! Takeda completed the acquisition of Shire today)
.
The fourth and fifth batches of national procurement are implemented, and many foreign enterprise promoters are affected
As of today, two batches of national procurement have been launched this year.
As you can see, in the past few months, many foreign company promoters have been affected by the company's adjustments
.
As you can see, in the past few months, many foreign company promoters have been affected by the company's adjustments
.
This week, two foreign companies made adjustments, mainly because the fourth batch of national sourcing and the fifth batch of national sourcing were not selected
.
.
One of the foreign companies, because they lost the fifth batch of national procurement, notified the team to adjust last week.
Today, many people have gone to Beijing, Hangzhou and other places to sign the resignation agreement.
The compensation is N+2.
After the results were announced, some people left and some were transferred.
After leaving another group this time, only a small number of dedicated line representatives were retained
.
Today, many people have gone to Beijing, Hangzhou and other places to sign the resignation agreement.
The compensation is N+2.
After the results were announced, some people left and some were transferred.
After leaving another group this time, only a small number of dedicated line representatives were retained
.
Another foreign company failed in the fourth batch of national sourcing products because of its variety, and the product will soon be handed over to other companies for promotion.
It is estimated that some of the promoters responsible for the product will also be affected
.
It is estimated that some of the promoters responsible for the product will also be affected
.
On February 8 this year, the fourth batch of national sources announced the results of the selection of 45 varieties, which began at the end of April and were implemented in all provinces across the country until the end of May.
On June 28, the results of the fifth batch of 62 varieties of national sources were announced.
, And it is expected to be implemented nationwide in October
.
On June 28, the results of the fifth batch of 62 varieties of national sources were announced.
, And it is expected to be implemented nationwide in October
.
In the past few months, many foreign and domestic companies have been affected by this to make organizational structure adjustments, so I will not list them all here
.
.
It is expected that by the end of this year, the sixth batch of national procurement may start
.
.
